These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12577127)

  • 21. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
    Yang TS; Wang BC; Chang SP; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):452-6. PubMed ID: 7634183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
    Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A
    J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer: a review.
    Elter K; Nelson LR
    Obstet Gynecol Surv; 2001 Sep; 56(9):576-88. PubMed ID: 11524623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GnRH agonists vs antagonists.
    Tarlatzis BC; Kolibianakis EM
    Best Pract Res Clin Obstet Gynaecol; 2007 Feb; 21(1):57-65. PubMed ID: 17049460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH.
    Peñarrubia J; Fábregues F; Creus M; Manau D; Casamitjana R; Guimerá M; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2003 Dec; 18(12):2689-97. PubMed ID: 14645193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GnRH agonists, antagonists, and assisted conception.
    van Loenen AC; Huirne JA; Schats R; Hompes PG; Lambalk CB
    Semin Reprod Med; 2002 Nov; 20(4):349-64. PubMed ID: 12536358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of gonadotropin-releasing hormone antagonists in in vitro fertilization.
    Diedrich K; Ludwig M; Felberbaum RE
    Semin Reprod Med; 2001 Sep; 19(3):213-20. PubMed ID: 11679902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
    Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulsatile gonadotrophin releasing hormone stimulation after medium-term pituitary suppression in polycystic ovary syndrome.
    Scheele F; Hompes PG; van der Meer M; Schoute E; Schoemaker J
    Hum Reprod; 1993 Nov; 8 Suppl 2():197-9. PubMed ID: 8276960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
    Datta AK; Eapen A; Birch H; Kurinchi-Selvan A; Lockwood G
    Reprod Biomed Online; 2014 Nov; 29(5):552-8. PubMed ID: 25246126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gonadotropin-releasing hormone antagonist protocol--the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
    Kol S; Homburg R; Alsbjerg B; Humaidan P
    Acta Obstet Gynecol Scand; 2012 Jun; 91(6):643-7. PubMed ID: 22428986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does endometrial integrin expression in endometriosis patients predict enhanced in vitro fertilization cycle outcomes after prolonged GnRH agonist therapy?
    Surrey ES; Lietz AK; Gustofson RL; Minjarez DA; Schoolcraft WB
    Fertil Steril; 2010 Feb; 93(2):646-51. PubMed ID: 19171333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GnRH-antagonists in reproductive medicine.
    Griesinger G; Felberbaum R; Diedrich K
    Arch Gynecol Obstet; 2005 Dec; 273(2):71-8. PubMed ID: 15991015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.
    O'Neill KE; Senapati S; Dokras A
    Fertil Steril; 2015 Jan; 103(1):264-9. PubMed ID: 25450300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients.
    Hwang JL; Chen SU; Chen HJ; Chen HF; Yang YS; Chang CH; Seow KM; Tzeng CR; Lin YH
    J Formos Med Assoc; 2018 Jun; 117(6):535-540. PubMed ID: 28830648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GnRH analog administration in patients with polycystic ovarian disease.
    Meden-Vrtovec H
    Int J Gynaecol Obstet; 1995 Aug; 50(2):179-83. PubMed ID: 7589755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.